Glaukos Corporation Stock Prediction
AI-powered sentiment analysis and prediction trends for GKOS, updated each market day.
GKOS AI Sentiment
AI sees no strong directional signal for Glaukos Corporation stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Glaukos Corporation
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Sector
Exchange
Market Cap
$6,937,514,093
Cap Tier
Employees
1,094
Headquarters
ALISO VIEJO, CA
Listed Since
June 25, 2015
Website
GKOS Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
GKOS Volatility
Glaukos Corporation has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
